VRX Valeant Pharmaceuticals International Inc.

13.77
-0.02  -0%
Previous Close 13.79
Open 13.86
Price To book 1.23
Market Cap 4782737171
Shares 347,330,223
Volume 5,069,190
Short Ratio 2.44
Av. Daily Volume 13,247,983

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

CRL issued August 7, 2017.
Latanoprostene bunod
Open angle glaucoma (OAG) or ocular hypertension (OHT)
Phase 3 enrollment to be completed in 2017.
Loteprednol Gel 0.38%
Ocular Inflammation
PDUFA date December 27, 2017.
Luminesse
Eye Brightener
Regulatory filing due 2H 2017.
IDP-122
Psoriasis
Regulatory filing due 2H 2017.
IDP-121
Acne
Phase 3 trial to be initiated 2H 2017.
IDP-120
Acne
Phase 3 data released January 10, 2017 - endpoints met. NDA filing announced September 5, 2017.
IDP-118
Psoriasis
Phase 3 trial to be initiated 2H 2017.
DP-123
Psoriasis
Approved February 15, 2017.
Brodalumab
Psoriasis
Phase 2 data due 1H 2017 according to latest company guidance. Timeline has passed so assume data release 3Q 2017.
SAN-300
Rheumatoid Arthritis

Latest News

  1. GlassHouse: NuVasive Using The 'Valeant Playbook' To Deceive Investors
  2. Valeant Pharmaceuticals: Is A New Drug Approval On The Horizon?
  3. What You Should Know About The Drug Approval Valeant Could Receive This Week
  4. Valeant To Participate At The Cantor Fitzgerald Global Healthcare Conference
  5. Valeant Commits $200,000 to Support Hurricane Relief Efforts
  6. Own Alphabet Inc. Stock? Antitrust Is on the Horizon
  7. Valeant Pharmaceuticals Intl Inc (VRX) Stock Is STILL Too Ugly to Buy
  8. See what the IHS Markit Score report has to say about Valeant Pharmaceuticals International Inc.
  9. Today's Research Reports on Trending Tickers: Endo International and Valeant Pharmaceuticals
  10. DST faces class action over profit-sharing plan
  11. Buy Amazon, short Valeant among the top picks out of last year's Delivering Alpha
  12. Follow the Crucial '$20 Level Rule' When Trading Stocks
  13. This Clear Catalyst Sent Valeant Pharmaceuticals Intl. Inc. 18% Lower in August
  14. $20 Should Be Your Cutoff Point
  15. Valeant To Participate At The Morgan Stanley Global Healthcare Conference
  16. Why Mallinckrodt Got Crushed
  17. Ortho Dermatologics Submits New Drug Application To The U.S. Food And Drug Administration For Psoriasis Treatment IDP-118

SEC Filings

  1. SC 13D - General statement of acquisition of beneficial ownership 171019031
  2. 10-Q - Quarterly report [Sections 13 or 15(d)] 171015575
  3. 8-K - Current report 171013203
  4. SC 13D - General statement of acquisition of beneficial ownership 17930150
  5. 8-K - Current report 17918583
  6. 8-K - Current report 17901255
  7. SD - 17880633
  8. 10-Q - Quarterly report [Sections 13 or 15(d)] 17827556
  9. 8-K - Current report 17824387
  10. 8-K - Current report 17814074